Novo Nordisk
-
Dünyadan
Why Denmark can’t use Ozempic as a trump card with the US in Greenland talks
Novo Nordisk, the Danish manufacturer of weight-loss drugs Ozempic and Wegovy, has a large market share in the US. But…
Devamını Oku » -
Dünyadan
Novo Nordisk keeps growing, fuelling hopes of a stock rebound
Novo Nordisk reported 18% sales growth in the first half of 2025, despite a profit warning that triggered a record…
Devamını Oku » -
Dünyadan
Novo Nordisk shares jump after Wegovy price cuts announced
Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its weight-loss treatment Wegovy.
Devamını Oku » -
Dünyadan
How Ozempic Is Transforming a Small Danish Town
As the sun sets over the harbor in Kalundborg, a small town about 60 miles west of Copenhagen, light streams…
Devamını Oku » -
Dünyadan
Novo Nordisk crossroads: Can the pharma giant address the supply dilemma?
Novo Nordisk faces a pivotal moment as it grapples with supply issues amid soaring demand for its weight-loss drugs. Despite…
Devamını Oku » -
Dünyadan
Novo Nordisk ascent: Will Europe’s biggest company continue to soar?
In the wake of substantial growth, Novo Nordisk's stock price has climbed to near-peak levels, with investors asking whether the…
Devamını Oku » -
Dünyadan
Denmark’s Novo Nordisk invests €2.1 billion in France
Danish pharmaceutical giant Novo Nordisk has announced major investment in a French production site to expand the capacity and manufacturing…
Devamını Oku » -
Dünyadan
Danish pharmaceutical invests €2.1 billion in France
On Thursday, Danish pharmaceutical giant Novo Nordisk announced a major investment in a French production site to expand the capacity…
Devamını Oku »
